NasdaqCM - Delayed Quote • USD
MEI Pharma, Inc. (MEIP)
At close: April 19 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -1.52 | -1.59 | 3.28 | -5.85 |
| Low Estimate | -1.7 | -1.72 | 3.24 | -6.72 |
| High Estimate | -1.34 | -1.46 | 3.33 | -4.98 |
| Year Ago EPS | -2.32 | -1.51 | -4.78 | 3.28 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | 40k | 50k | 65.38M | 6.25M |
| Low Estimate | -- | -- | 65.3M | -- |
| High Estimate | 70k | 100k | 65.47M | 12.5M |
| Year Ago Sales | 460k | 1.46M | 48.82M | 65.38M |
| Sales Growth (year/est) | -91.30% | -96.60% | 33.90% | -90.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.87 | -2.41 | -2.12 | -1.32 |
| EPS Actual | -2.32 | -1.51 | 8.46 | -1.66 |
| Difference | 0.55 | 0.9 | 10.58 | -0.34 |
| Surprise % | 19.20% | 37.30% | 499.10% | -25.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.52 | -1.59 | 3.28 | -5.85 |
| 7 Days Ago | -1.52 | -1.59 | 3.28 | -5.85 |
| 30 Days Ago | -1.52 | -1.59 | 3.28 | -5.85 |
| 60 Days Ago | -1.35 | -1.42 | 3.76 | -5.36 |
| 90 Days Ago | -1.34 | -1.41 | 3.88 | -5.2 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | MEIP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 34.50% | -- | -- | 1.60% |
| Next Qtr. | -5.30% | -- | -- | 10.50% |
| Current Year | 168.60% | -- | -- | 5.20% |
| Next Year | -278.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -0.10% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Stifel: Hold to Hold | 4/12/2024 |
| Maintains | Stifel: Hold to Hold | 2/14/2024 |
| Maintains | Stifel: Hold to Hold | 9/27/2023 |
| Maintains | Brookline Capital: Buy to Buy | 5/23/2023 |
| Maintains | Stifel: Hold to Hold | 5/12/2023 |
Related Tickers
REVB Revelation Biosciences, Inc.
2.2400
+1.36%
PRTC PureTech Health plc
26.15
-0.46%
DSGN Design Therapeutics, Inc.
3.7000
-1.07%
BOLT Bolt Biotherapeutics, Inc.
1.1100
-2.63%
AKTX Akari Therapeutics, Plc
1.1662
-0.32%
GNTA Genenta Science S.p.A.
3.9010
-0.74%
CYCN Cyclerion Therapeutics, Inc.
3.5000
+5.58%
LXEO Lexeo Therapeutics, Inc.
12.05
-0.17%
GRI GRI Bio, Inc.
0.5279
+2.43%
ANTX AN2 Therapeutics, Inc.
2.4700
+3.78%